Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
December 17, 2024 08:50 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2...
Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action
December 04, 2024 09:20 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Pankaj Mohan, CEO of Sonnet discusses what this publication means in a Virtual Investor “What This Means” segment; access here PRINCETON, NJ, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet...
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
November 12, 2024 09:15 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug...
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
November 06, 2024 13:20 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted...
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
October 17, 2024 08:45 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
September 30, 2024 09:00 ET
|
Sonnet BioTherapeutics Holdings, Inc.
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Provides interested parties the ability to ask questions and submit...
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
September 25, 2024 08:30 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted...
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
September 18, 2024 08:30 ET
|
Sonnet BioTherapeutics Holdings, Inc.
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE...